分组1 - Canadian Pacific Kansas City reported quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $0.82 per share, but showing an increase from $0.77 per share a year ago, resulting in an earnings surprise of -1.22% [1] - The company posted revenues of $2.67 billion for the quarter ended June 2025, which was 4.08% below the Zacks Consensus Estimate and slightly above the year-ago revenues of $2.63 billion [2] - Over the last four quarters, Canadian Pacific Kansas City has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] 分组2 - The stock has gained approximately 5.3% since the beginning of the year, compared to the S&P 500's gain of 8.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is $0.86 on revenues of $2.79 billion, and for the current fiscal year, it is $3.44 on revenues of $11.31 billion [7] 分组3 - The Zacks Industry Rank indicates that the Transportation - Rail sector is currently in the top 37% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - The estimate revisions trend for Canadian Pacific Kansas City was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Insights - Fair Isaac (FICO) reported quarterly earnings of $8.57 per share, exceeding the Zacks Consensus Estimate of $7.73 per share, and showing an increase from $6.25 per share a year ago, resulting in an earnings surprise of +10.87% [1] - The company posted revenues of $536.42 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.40%, and up from $447.85 million year-over-year [2] - Fair Isaac shares have declined approximately 24.4% year-to-date, contrasting with the S&P 500's gain of 8.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $7.97, with expected revenues of $528.91 million, and for the current fiscal year, the EPS estimate is $29.42 on revenues of $1.99 billion [7] - The estimate revisions trend for Fair Isaac was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Computers - IT Services industry, to which Fair Isaac belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Amdocs (DOX), another company in the same industry, is expected to report quarterly earnings of $1.71 per share, reflecting a year-over-year change of +5.6%, with revenues anticipated to be $1.13 billion, down 9.7% from the previous year [9][10]

分组1 - Hawkins reported quarterly earnings of $1.4 per share, exceeding the Zacks Consensus Estimate of $1.33 per share, and showing a slight decrease from $1.38 per share a year ago, resulting in an earnings surprise of +5.26% [1] - The company achieved revenues of $293.27 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.38% and increasing from $255.88 million year-over-year [2] - Hawkins shares have increased approximately 30.9% year-to-date, significantly outperforming the S&P 500's gain of 8.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.19 on revenues of $278.75 million, while for the current fiscal year, the estimate is $4.28 on revenues of $1.08 billion [7] - The Zacks Industry Rank indicates that the Chemical - Specialty sector is currently in the bottom 32% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] 分组3 - The estimate revisions trend for Hawkins was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Hologic reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, and showing a slight increase from $1.06 per share a year ago, resulting in an earnings surprise of +2.86% [1] - The company posted revenues of $1.02 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.68%, compared to revenues of $1.01 billion in the same quarter last year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.04 billion, while for the current fiscal year, the estimate is $4.19 on revenues of $4.08 billion [7] - The trend of estimate revisions for Hologic was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - Hologic operates within the Zacks Medical - Instruments industry, which is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges for stock performance compared to higher-ranked industries [8] - The performance of Hologic's stock may be influenced by the overall outlook for the medical instruments industry, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]

Company Performance - Wave Life Sciences reported a quarterly loss of $0.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.29, and compared to a loss of $0.25 per share a year ago, indicating a negative earnings surprise of -6.90% [1] - The company posted revenues of $8.7 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31.16%, and down from $19.69 million in the same quarter last year [2] - Over the last four quarters, Wave Life Sciences has surpassed consensus EPS estimates only once and has also topped consensus revenue estimates just once [2] Stock Performance - Wave Life Sciences shares have declined approximately 32.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Wave Life Sciences is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $14.5 million, and for the current fiscal year, it is -$1.12 on revenues of $49.27 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Wave Life Sciences operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable industry environment [8]

Earnings Performance - Monro Muffler Brake reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, and matching the earnings from the previous year [1] - The earnings surprise was +29.41%, contrasting with a prior quarter where the company posted a loss of $0.09 per share, resulting in a surprise of -200% [1][2] - Over the last four quarters, Monro has surpassed consensus EPS estimates only once [2] Revenue Insights - The company generated revenues of $301.04 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.55% and showing an increase from $293.18 million year-over-year [2] - Monro has exceeded consensus revenue estimates three times in the last four quarters [2] Stock Performance and Outlook - Monro shares have declined approximately 34.2% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $299.29 million, and for the current fiscal year, it is $0.74 on revenues of $1.19 billion [7] - The Zacks Industry Rank places the Consumer Services - Miscellaneous sector in the bottom 12% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Estimate Revisions and Ratings - Prior to the earnings release, the estimate revisions trend for Monro was favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Etsy (ETSY) came out with quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -53.70%. A quarter ago, it was expected that this online crafts marketplace would post earnings of $0.5 per share when it actually produced earnings of $0.46, delivering a surprise of -8%. Over the last four quarters, the c ...

Core Viewpoint - Stepan Co. reported quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.92 per share, representing a significant earnings surprise of -43.48% [1][2] Financial Performance - The company posted revenues of $594.69 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.49%, compared to $556.41 million in the same quarter last year [2] - Over the last four quarters, Stepan Co. has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Stepan Co. shares have declined approximately 14.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Stepan Co. is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $583.9 million, and for the current fiscal year, it is $3.33 on revenues of $2.34 billion [7] - The estimate revisions trend for Stepan Co. was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Chemical - Diversified industry, to which Stepan Co. belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Company Performance - SunCoke Energy reported quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.15 per share, and down from $0.25 per share a year ago, representing an earnings surprise of -86.67% [1] - The company posted revenues of $434.1 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 25.10%, but down from year-ago revenues of $470.9 million [2] - Over the last four quarters, SunCoke has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - SunCoke shares have lost about 22.6% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The current Zacks Rank for SunCoke is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.15 on $347 million in revenues, and $0.64 on $1.48 billion in revenues for the current fiscal year [7] - The outlook for the coal industry, where SunCoke operates, is currently in the bottom 17% of the Zacks industries, which may materially impact stock performance [8] Industry Context - Peabody Energy, another company in the coal industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of -102.8%, with revenues expected to be $937.6 million, down 10% from the year-ago quarter [9][10]

Core Viewpoint - InMode reported quarterly earnings of $0.47 per share, exceeding the Zacks Consensus Estimate of $0.43 per share, and showing an increase from $0.34 per share a year ago, indicating a positive earnings surprise of +9.30% [1][2] Financial Performance - The company achieved revenues of $95.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.11%, and up from $86.45 million year-over-year [2] - Over the last four quarters, InMode has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - InMode shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $88.4 million, and for the current fiscal year, it is $1.68 on revenues of $365 million [7] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of InMode's stock may be influenced by the overall outlook of the industry [8]